(BNTX) BioNTech SE - Ratings and Ratios
Immunotherapies, Cancer Treatments, Vaccines, Medicines, Therapies
BNTX EPS (Earnings per Share)
BNTX Revenue
Description: BNTX BioNTech SE
BioNTech SE is a German biotechnology company that focuses on developing and commercializing immunotherapies for cancer and infectious diseases. The company has a diverse pipeline of candidates in various stages of clinical trials, targeting a range of solid tumors and specific cancer types, including melanoma, non-small cell lung cancer, and urothelial carcinoma.
Some of the key pipeline candidates include BNT111, BNT113, and BNT311/GEN1046 (acasunlimab), which are in Phase 2 and Phase 3 clinical trials for advanced melanoma, head and neck squamous cell carcinoma, and solid tumors, respectively. Additionally, BNT327 is in Phase 1/2, 2, and 3 clinical trials for multiple indications, including small cell lung cancer, triple-negative breast cancer, and advanced solid tumors.
From a financial perspective, BioNTech SE has a market capitalization of approximately $27.1 billion USD, with a forward P/E ratio of 7.04. The companys return on equity (ROE) is currently negative, at -4.04%. Key performance indicators (KPIs) to monitor include revenue growth, R&D expenses as a percentage of revenue, and cash burn rate. The companys cash position and burn rate will be crucial in determining its ability to continue funding its pipeline development.
Other relevant KPIs for BioNTech SE include its pipeline progression, particularly the success of its lead candidates in clinical trials, and its partnerships with other pharmaceutical companies, such as Pfizer and Genentech. The companys ability to successfully commercialize its products and navigate the complex regulatory landscape will be critical to its long-term success.
BNTX Stock Overview
| Market Cap in USD | 23,256m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-10-10 |
BNTX Stock Ratings
| Growth Rating | -45.7% |
| Fundamental | 21.0% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | -33.3% |
| Analyst Rating | 4.38 of 5 |
BNTX Dividends
Currently no dividends paidBNTX Growth Ratios
| Growth Correlation 3m | -22.1% |
| Growth Correlation 12m | -49.7% |
| Growth Correlation 5y | -46.1% |
| CAGR 5y | -9.85% |
| CAGR/Max DD 3y | -0.17 |
| CAGR/Mean DD 3y | -0.24 |
| Sharpe Ratio 12m | -1.12 |
| Alpha | -17.33 |
| Beta | 0.711 |
| Volatility | 62.26% |
| Current Volume | 1410.5k |
| Average Volume 20d | 907.7k |
| Stop Loss | 93.4 (-4.6%) |
| Signal | 0.00 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-347.4m TTM) > 0 and > 6% of Revenue (6% = 172.7m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -11.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 489.1% (prev 588.9%; Δ -99.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.08 (>3.0%) and CFO -1.77b <= Net Income -347.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (241.6m) change vs 12m ago 1.64% (target <= -2.0% for YES) |
| Gross Margin 79.84% (prev 64.42%; Δ 15.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 13.12% (prev 12.11%; Δ 1.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -9.21 (EBITDA TTM -227.6m / Interest Expense TTM 52.7m) >= 6 (WARN >= 3) |
Altman Z'' 12.60
| (A) 0.65 = (Total Current Assets 15.93b - Total Current Liabilities 1.85b) / Total Assets 21.64b |
| (B) 0.85 = Retained Earnings (Balance) 18.30b / Total Assets 21.64b |
| warn (B) unusual magnitude: 0.85 — check mapping/units |
| (C) -0.02 = EBIT TTM -485.6m / Avg Total Assets 21.94b |
| (D) 5.45 = Book Value of Equity 17.07b / Total Liabilities 3.13b |
| Total Rating: 12.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 20.96
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -4.04% = -2.02 |
| 3. FCF Margin -8.50% = -3.19 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -1.18 = -2.50 |
| 6. ROIC - WACC -11.06% = -12.50 |
| 7. RoE -1.83% = -0.30 |
| 8. Rev. Trend -56.29% = -2.81 |
| 9. Rev. CAGR -60.95% = -2.50 |
| 10. EPS Trend -68.46% = -1.71 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of BNTX shares?
Over the past week, the price has changed by -4.66%, over one month by -13.78%, over three months by -7.95% and over the past year by -20.73%.
Is BioNTech SE a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BNTX is around 82.77 USD . This means that BNTX is currently overvalued and has a potential downside of -15.44%.
Is BNTX a buy, sell or hold?
- Strong Buy: 13
- Buy: 3
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BNTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 136.2 | 39.1% |
| Analysts Target Price | 136.2 | 39.1% |
| ValueRay Target Price | 92.3 | -5.7% |
Last update: 2025-09-16 04:31
BNTX Fundamental Data Overview
CCE Cash And Equivalents = 14.04b EUR (Cash And Short Term Investments, last quarter)
P/E Forward = 7.0373
P/S = 8.0796
P/B = 1.0739
P/EG = 0.0449
Beta = 1.401
Revenue TTM = 2.88b EUR
EBIT TTM = -485.6m EUR
EBITDA TTM = -227.6m EUR
Long Term Debt = 217.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 52.4m EUR (from shortTermDebt, last quarter)
Debt = 269.6m EUR (Calculated: Short Term 52.4m + Long Term 217.2m)
Net Debt = -10.00b EUR (from netDebt column, last quarter)
Enterprise Value = 6.06b EUR (19.82b + Debt 269.6m - CCE 14.04b)
Interest Coverage Ratio = -9.21 (Ebit TTM -485.6m / Interest Expense TTM 52.7m)
FCF Yield = -4.04% (FCF TTM -244.6m / Enterprise Value 6.06b)
FCF Margin = -8.50% (FCF TTM -244.6m / Revenue TTM 2.88b)
Net Margin = -12.07% (Net Income TTM -347.4m / Revenue TTM 2.88b)
Gross Margin = 79.84% ((Revenue TTM 2.88b - Cost of Revenue TTM 580.2m) / Revenue TTM)
Tobins Q-Ratio = 0.35 (Enterprise Value 6.06b / Book Value Of Equity 17.07b)
Interest Expense / Debt = 1.26% (Interest Expense 3.40m / Debt 269.6m)
Taxrate = 21.0% (US default)
NOPAT = -485.6m (EBIT -485.6m, no tax applied on loss)
Current Ratio = 8.61 (Total Current Assets 15.93b / Total Current Liabilities 1.85b)
Debt / Equity = 0.01 (Debt 269.6m / last Quarter total Stockholder Equity 18.51b)
Debt / EBITDA = -1.18 (Net Debt -10.00b / EBITDA -227.6m)
Debt / FCF = -1.10 (Debt 269.6m / FCF TTM -244.6m)
Total Stockholder Equity = 19.00b (last 4 quarters mean)
RoA = -1.61% (Net Income -347.4m, Total Assets 21.64b )
RoE = -1.83% (Net Income TTM -347.4m / Total Stockholder Equity 19.00b)
RoCE = -2.53% (Ebit -485.6m / (Equity 19.00b + L.T.Debt 217.2m))
RoIC = -2.52% (NOPAT -485.6m / Invested Capital 19.25b)
WACC = 8.54% (E(19.82b)/V(20.09b) * Re(8.64%)) + (D(269.6m)/V(20.09b) * Rd(1.26%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -30.30 | Cagr: -0.51%
Discount Rate = 8.64% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -244.6m)
Revenue Correlation: -56.29 | Revenue CAGR: -60.95%
Rev Growth-of-Growth: 105.0
EPS Correlation: -68.46 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 131.4
Additional Sources for BNTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle